RS50262B2 - Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva - Google Patents
Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstvaInfo
- Publication number
- RS50262B2 RS50262B2 RS14502A RSP20020145A RS50262B2 RS 50262 B2 RS50262 B2 RS 50262B2 RS 14502 A RS14502 A RS 14502A RS P20020145 A RSP20020145 A RS P20020145A RS 50262 B2 RS50262 B2 RS 50262B2
- Authority
- RS
- Serbia
- Prior art keywords
- drospirenone
- ethinylestradiol
- composition
- active agent
- dosage units
- Prior art date
Links
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 title abstract 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 title abstract 4
- 229960002568 ethinylestradiol Drugs 0.000 title abstract 3
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 title abstract 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title abstract 2
- 229960004845 drospirenone Drugs 0.000 title abstract 2
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000000654 additive Substances 0.000 abstract 1
- 229940007690 drospirenone and ethinylestradiol Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Abstract
Farmaceutska kompozicija koja sadrži, kao prvo aktivno sredstvo. 6β.7β; 15β,16β-dimetilen-3-okso-17α-pregn-4-en-21,17-karbolakton (drospirenon) u količini koja odgovara jednoj dnevnoj dozi, nakom davanja kompozicije, od oko 2 mg do oko 4 mg, i, kao drugo aktivno sredstvo, 17α-etinilestradiol (etinilestra-diol) u količini koja odgovara dnevnoj dozi od oko 0,01 mg do oko 0,05 mg, zajedno sa jednim ili više farmaceutski prihvatljivih nosača ili neutralnih dodataka. Kod jednog posebnog izvođenja, kompozicija se sastoji od više odvojeno pakovanih i pojedinačno odvojivih dnevnih doznih jedinica postavljenih u jednu jedinicu pakovanja i namenjenih za oralno davanje u trajanju od najmanje 21 dan zaredom, pri čemu pomenute dnevne dozne jedinice sadrže svaka jednu kombinaciju drospirenona i etinilestradiola. Kompozicija može dalje sadržati 7 ili manje dnevnih doznih jedinica koje ne sadrže nikakvo aktivno sredstvo ili sadrže sam etinilestradiol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38627499A | 1999-08-31 | 1999-08-31 | |
EP99202826 | 1999-08-31 | ||
PCT/IB2000/001213 WO2001015701A1 (en) | 1999-08-31 | 2000-08-31 | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
Publications (1)
Publication Number | Publication Date |
---|---|
RS50262B2 true RS50262B2 (sr) | 2018-10-31 |
Family
ID=26153359
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS14502A RS50262B2 (sr) | 1999-08-31 | 2000-08-31 | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva |
YU14502A RS50262B (sr) | 1999-08-31 | 2000-08-31 | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva |
RSP-2009/0134A RS20090134A (en) | 1999-08-31 | 2000-08-31 | Pharmaceutical combinattion of ethinylestradiol and drospinenone for use as a contraceptive |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU14502A RS50262B (sr) | 1999-08-31 | 2000-08-31 | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva |
RSP-2009/0134A RS20090134A (en) | 1999-08-31 | 2000-08-31 | Pharmaceutical combinattion of ethinylestradiol and drospinenone for use as a contraceptive |
Country Status (26)
Country | Link |
---|---|
EP (4) | EP2044941A1 (sr) |
JP (2) | JP4354667B2 (sr) |
KR (2) | KR101019361B1 (sr) |
AT (3) | ATE254464T1 (sr) |
AU (4) | AU780330B2 (sr) |
BG (1) | BG66114B1 (sr) |
BR (1) | BR0014159A (sr) |
CY (3) | CY1108990T1 (sr) |
CZ (1) | CZ300514B6 (sr) |
DE (5) | DE122009000006I2 (sr) |
DK (3) | DK1598069T3 (sr) |
EE (1) | EE05128B1 (sr) |
ES (3) | ES2325589T3 (sr) |
HK (3) | HK1047247B (sr) |
HR (1) | HRP20070188B1 (sr) |
HU (1) | HU227207B1 (sr) |
IL (1) | IL148339A0 (sr) |
ME (2) | ME00329B (sr) |
NO (1) | NO326860B1 (sr) |
NZ (1) | NZ517845A (sr) |
PL (1) | PL199028B1 (sr) |
PT (3) | PT1214076E (sr) |
RS (3) | RS50262B2 (sr) |
SI (3) | SI1214076T1 (sr) |
TW (1) | TWI276436B (sr) |
WO (1) | WO2001015701A1 (sr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4354667B2 (ja) * | 1999-08-31 | 2009-10-28 | バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ |
WO2001052857A1 (en) * | 2000-01-18 | 2001-07-26 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
JO2334B1 (en) * | 2000-01-18 | 2006-06-28 | باير شيرنغ فارما اكتنجيسيلشافت | Drospirenone for hormone replacement therapy |
WO2002049674A1 (en) * | 2000-12-20 | 2002-06-27 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
BR0309780A (pt) * | 2002-04-26 | 2005-03-22 | Schering Aktiengellschaft | Tratamento da hipertensão em mulheres recebendo terapia de reposição hormonal |
US7786101B2 (en) | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
EP1980242B1 (en) * | 2004-03-10 | 2010-08-11 | Bayer Schering Pharma Aktiengesellschaft | Liquid compositions as a micro-emulsion pre-concentrate comprising drospirenone moleculary dispersed |
MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
EP1625849A1 (en) * | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
JP2008534522A (ja) * | 2005-03-30 | 2008-08-28 | ジェンファーム インク | 医薬組成物のための複合ステップ製造方法 |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
EP1900359A1 (en) * | 2006-09-16 | 2008-03-19 | KAIROSmed GmbH | Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception |
JP2010503632A (ja) * | 2006-09-16 | 2010-02-04 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 経口改良放出製剤 |
CA2683093A1 (en) * | 2007-04-05 | 2008-10-16 | Bayer Schering Pharma Aktiengesellschaft | New drospirenone/17.beta.-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
HUP0700826A3 (en) * | 2007-12-20 | 2010-03-29 | Richter Gedeon Nyrt | Coated tablet containing drospirenone and process for producing the same |
TW200946542A (en) * | 2008-03-10 | 2009-11-16 | Vladimir Hanes | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
TW200942242A (en) * | 2008-03-10 | 2009-10-16 | Rolf Schurmann | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
WO2009138224A1 (en) * | 2008-05-14 | 2009-11-19 | Helm Ag | Pharmaceutical composition comprising drospirenone |
DE102008037025C5 (de) | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
EP2398461A1 (en) * | 2009-02-18 | 2011-12-28 | Bayer Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
UY32836A (es) | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
CN102985070A (zh) * | 2010-04-15 | 2013-03-20 | 拜耳知识产权有限责任公司 | 用于hrt的极低剂量的固体口服剂型 |
AR081670A1 (es) * | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
IT202100008834A1 (it) | 2021-04-08 | 2022-10-08 | Ind Chimica Srl | Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina |
WO2023152658A1 (en) | 2022-02-10 | 2023-08-17 | Lupin Limited | Slow release drospirenone tablet composition |
WO2023165988A1 (en) * | 2022-03-01 | 2023-09-07 | Chemo Research, S.L. | Chewable oral contraceptive |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2652761C2 (de) | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE3051167C3 (de) * | 1979-01-24 | 1994-11-24 | Minnesota Mining & Mfg | Fluorierte Alkohole |
DE3051166C2 (en) | 1980-06-11 | 1990-10-18 | Schering Ag, 1000 Berlin Und 4709 Bergkamen, De | Compsns. for contraception or treatment of gynaecological disorders |
DE3347125A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
DE3682130D1 (de) * | 1985-07-15 | 1991-11-28 | Japan Res Dev Corp | Verfahren zur herstellung von ultrafeinen organischen verbindungen. |
DE3916112A1 (de) | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
ZA939566B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for dry blend compression od medicaments. |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
WO1996009056A1 (en) * | 1994-09-22 | 1996-03-28 | Akzo Nobel N.V. | Process of making dosage units by wet granulation |
DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
AU3888697A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
BR9710566A (pt) * | 1996-07-26 | 1999-08-17 | American Home Prod | M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio |
WO1998004268A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Oral contraceptive |
DE19633685C1 (de) | 1996-08-12 | 1997-10-09 | Schering Ag | Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens |
DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
JP4354667B2 (ja) * | 1999-08-31 | 2009-10-28 | バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ |
WO2001052857A1 (en) * | 2000-01-18 | 2001-07-26 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
-
2000
- 2000-08-31 JP JP2001519915A patent/JP4354667B2/ja not_active Expired - Lifetime
- 2000-08-31 DE DE200912000006 patent/DE122009000006I2/de active Active
- 2000-08-31 DK DK05076943T patent/DK1598069T3/da active
- 2000-08-31 ME MEP-2008-360A patent/ME00329B/me unknown
- 2000-08-31 EP EP08015966A patent/EP2044941A1/en not_active Withdrawn
- 2000-08-31 RS RS14502A patent/RS50262B2/sr unknown
- 2000-08-31 RS YU14502A patent/RS50262B/sr unknown
- 2000-08-31 AU AU65895/00A patent/AU780330B2/en not_active Expired
- 2000-08-31 SI SI200030308T patent/SI1214076T1/xx unknown
- 2000-08-31 EP EP00953387A patent/EP1214076B1/en not_active Revoked
- 2000-08-31 RS RSP-2009/0134A patent/RS20090134A/sr unknown
- 2000-08-31 EP EP05076943A patent/EP1598069B1/en not_active Revoked
- 2000-08-31 AT AT00953387T patent/ATE254464T1/de active
- 2000-08-31 ES ES05076943T patent/ES2325589T3/es not_active Expired - Lifetime
- 2000-08-31 DK DK03017743T patent/DK1380301T3/da active
- 2000-08-31 EE EEP200200110A patent/EE05128B1/xx not_active IP Right Cessation
- 2000-08-31 SI SI200031021T patent/SI1380301T1/sl unknown
- 2000-08-31 DK DK00953387T patent/DK1214076T3/da active
- 2000-08-31 ES ES03017743T patent/ES2319750T3/es not_active Expired - Lifetime
- 2000-08-31 SI SI200031034T patent/SI1598069T1/sl unknown
- 2000-08-31 KR KR1020077013070A patent/KR101019361B1/ko active IP Right Review Request
- 2000-08-31 DE DE60006692T patent/DE60006692T2/de not_active Expired - Lifetime
- 2000-08-31 ES ES00953387T patent/ES2211580T3/es not_active Expired - Lifetime
- 2000-08-31 CZ CZ20020615A patent/CZ300514B6/cs not_active IP Right Cessation
- 2000-08-31 AT AT03017743T patent/ATE420648T1/de active
- 2000-08-31 PT PT00953387T patent/PT1214076E/pt unknown
- 2000-08-31 PT PT03017743T patent/PT1380301E/pt unknown
- 2000-08-31 DE DE200912000007 patent/DE122009000007I2/de active Active
- 2000-08-31 HU HU0202500A patent/HU227207B1/hu unknown
- 2000-08-31 DE DE60042089T patent/DE60042089D1/de not_active Expired - Lifetime
- 2000-08-31 KR KR1020027002795A patent/KR100857344B1/ko active IP Right Review Request
- 2000-08-31 BR BR0014159-3A patent/BR0014159A/pt not_active Application Discontinuation
- 2000-08-31 EP EP03017743A patent/EP1380301B1/en not_active Revoked
- 2000-08-31 DE DE60041421T patent/DE60041421D1/de not_active Expired - Lifetime
- 2000-08-31 ME MEP-360/08A patent/MEP36008A/xx unknown
- 2000-08-31 WO PCT/IB2000/001213 patent/WO2001015701A1/en active Search and Examination
- 2000-08-31 NZ NZ51784500A patent/NZ517845A/xx not_active IP Right Cessation
- 2000-08-31 AT AT05076943T patent/ATE429231T1/de active
- 2000-08-31 PL PL354406A patent/PL199028B1/pl unknown
- 2000-08-31 IL IL14833900A patent/IL148339A0/xx active IP Right Grant
- 2000-08-31 PT PT05076943T patent/PT1598069E/pt unknown
- 2000-11-16 TW TW089124254A patent/TWI276436B/zh not_active IP Right Cessation
-
2002
- 2002-02-19 NO NO20020801A patent/NO326860B1/no not_active IP Right Cessation
- 2002-12-12 HK HK02109000.7A patent/HK1047247B/zh not_active IP Right Cessation
-
2004
- 2004-07-08 HK HK04104970.2A patent/HK1061968A1/xx not_active IP Right Cessation
-
2005
- 2005-05-13 AU AU2005202046A patent/AU2005202046B9/en not_active Expired
-
2006
- 2006-04-24 HK HK06104833.7A patent/HK1082432A1/xx not_active IP Right Cessation
- 2006-11-23 BG BG109749A patent/BG66114B1/bg unknown
-
2007
- 2007-05-04 HR HRP20070188AA patent/HRP20070188B1/hr not_active IP Right Cessation
-
2009
- 2009-01-22 AU AU2009200247A patent/AU2009200247B2/en not_active Expired
- 2009-03-02 JP JP2009048381A patent/JP2009143959A/ja active Pending
- 2009-04-14 CY CY20091100446T patent/CY1108990T1/el unknown
- 2009-07-22 CY CY20091100784T patent/CY1109252T1/el unknown
- 2009-09-25 CY CY2009015C patent/CY2009015I1/el unknown
-
2010
- 2010-10-01 AU AU2010226924A patent/AU2010226924A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS50262B2 (sr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
ME00292B (me) | Drospirenon za terapiju zamjene hormona | |
HRP20090418T1 (en) | Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate | |
NO327588B1 (no) | Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel | |
BG66095B1 (bg) | Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат | |
TR200003788A2 (tr) | Yavaş salımlı oral dozaj bileşim. | |
HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
KR890009407A (ko) | 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위 | |
HRP20080394T3 (en) | Peroral solid dosage form for contraception comprising dienogest and ethinylestradiol | |
TW200638951A (en) | Solid oral pharmaceutical form for contraception | |
MX2007009061A (es) | Preparacion farmaceutica para la anticoncepcion oral. | |
CA2248841A1 (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive method | |
ECSP003721A (es) | Una composicion farmaceutica para ser usada como anticonceptivo | |
PL1937274T3 (pl) | Zastosowanie walerianianu estradiolu w połączeniu z dienogestem do doustnej terapii dysfunkcyjnego krwawienia macicznego wraz z doustną antykoncepcją | |
TH54054B (th) | สารผสมทางเภสัชกรรมสำหรับใช้เป็นยาคุมกำเนิด | |
RS50849B (sr) | Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu | |
HRP20020666B1 (en) | Drospirenone for hormone replacement therapy | |
UY29378A1 (es) | Preparación farmaceutica para la anticoncepción oral | |
CO5280075A1 (es) | Drospirenona para terapia de reemplazo de hormonas | |
TH80557B (th) | ผลิตภัณฑ์ทางเภสัชกรรมสำหรับการคุมกำเนิดทางช่องปาก |